| 000 | 01804 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250514224903.0 | ||
| 264 | 0 | _c20050711 | |
| 008 | 200507s 0 0 eng d | ||
| 022 | _a0251-1649 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBalanescu, A | |
| 245 | 0 | 0 |
_aEarly and late effect of infliximab on circulating dendritic cells phenotype in rheumatoid arthritis patients. _h[electronic resource] |
| 260 |
_bInternational journal of clinical pharmacology research _c2005 |
||
| 300 |
_a9-18 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 | _aAntigens, CD |
| 650 | 0 | 4 |
_aAntirheumatic Agents _xadverse effects |
| 650 | 0 | 4 |
_aArthritis, Rheumatoid _xblood |
| 650 | 0 | 4 |
_aCD11c Antigen _xbiosynthesis |
| 650 | 0 | 4 |
_aDendritic Cells _xdrug effects |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFlow Cytometry |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulins _xbiosynthesis |
| 650 | 0 | 4 | _aInfliximab |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMembrane Glycoproteins _xbiosynthesis |
| 650 | 0 | 4 |
_aMethotrexate _xadministration & dosage |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPhenotype |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xantagonists & inhibitors |
| 650 | 0 | 4 | _aCD83 Antigen |
| 700 | 1 | _aRadu, E | |
| 700 | 1 | _aNat, R | |
| 700 | 1 | _aRegalia, T | |
| 700 | 1 | _aBojinca, V | |
| 700 | 1 | _aIonescu, R | |
| 700 | 1 | _aBalanescu, S | |
| 700 | 1 | _aSavu, C | |
| 700 | 1 | _aPredeteanu, D | |
| 773 | 0 |
_tInternational journal of clinical pharmacology research _gvol. 25 _gno. 1 _gp. 9-18 |
|
| 999 |
_c15531381 _d15531381 |
||